EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Probiotic Combination of Limosilactobacillus reuteri and Clostridium butyricum Ameliorates 5‐Fluorouracil‐Induced Intestinal Mucositis in Rats by Strengthening Barrier Integrity and Modulating Immuno‐Microbial Homeostasis

Pui-Ying Leong iD, Wen-Chen Chuang, Jiunn-Liang Ko iD, Jiunn-Wang Liao, Liang-Chuan Chen, Yi-Hsuan Tsai, Chu-Chyn Ou iD

Journal of Cellular Physiology · 2026

DOI: 10.1002/jcp.70183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2026. Verfasst von Pui-Ying Leong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology & Rheumatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Clostridium butyricum, Probiotics, Fluorouracil, Mucositis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chung Shan Medical University Hospital, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

5‐fluorouracil (5FU)‐induced intestinal mucositis significantly limits its clinical utility and compromises patient outcomes. Building on our previous finding that a specific probiotic formulation, consisting of Limosilactobacillus reuteri BCRC 80379 and Clostridium butyricum MIYAIRI 588 (collectively referred to as LCs), mitigated cisplatin‐induced mucositis, this study evaluated the prophylactic efficacy and underlying mechanisms of LCs against 5FU‐induced mucositis in Wistar rats. Rats were divided into control, 5FU‐only, and 5FU+LCs groups. LCs was orally administered daily for 21 days before and throughout the 5FU treatment (50 mg/kg/day for 5 days). Intestinal tissues were analyzed using histological, molecular, and microbiological approaches. Pretreatment with LCs significantly attenuated 5FU‐induced small intestinal damage, as evidenced by improved mucosal structure (e.g., increased villus height, crypt depth, and goblet cell density), along with reduced inflammatory cell infiltration. Moreover, LCs reinforced the intestinal barrier by upregulating genes associated with the mucus layer ( Muc2 ) and tight junctions ( Ocln , Tjp1 , and Cldn1 ). LCs also suppressed the TLR4/MyD88/NF‐κB pathway, leading to reduced levels of pro‐inflammatory mediators (e.g., TNF‐α, IL‐1β, and MPO) while elevating key regulatory mediators such as IL‐10 and secretory IgA (sIgA). Furthermore, microbial profiling revealed that LCs beneficially reshaped gut microbiota composition by reducing opportunistic pathogens (e.g., Escherichia‐Shigella and Enterobacter ). These microbial changes were accompanied by a favorable immune modulation, including decreased pro‐inflammatory markers and increased homeostatic mediators. Collectively, these findings suggest that LCs mitigates 5FU‐induced mucositis through coordinated regulation of intestinal barrier integrity, immune responses, and gut microbiota, highlighting its potential as a probiotic‐based approach for managing chemotherapy‐induced intestinal injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridium butyricumProbioticsFluorouracilMucositisLimosilactobacillus reuteriIntestinal MucosaAnimalsIntestinal Barrier FunctionRats, WistarRatsHomeostasisMaleGastrointestinal Microbiome

Stichwörter der Autor:innen

5‐FluorouracilClostridium butyricum MIYAIRI 588Limosilactobacillus reuteri BCRC 80379intestinal barriermicrobiotamucositis

Substanzen

Fluorouracil

Autor:innen und Institutionen

  • Division of Allergy, Immunology & Rheumatology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Nutrition, Chung Shan Medical University, Taichung, Taiwan.
  • Graduate Institute of Veterinary Pathobiology, National Chung Hsing University, Taichung, Taiwan.
  • Department of Nutrition, Chung Shan Medical University Hospital, Taichung, Taiwan.

ORCID-Profile: Pui-Ying Leong, Jiunn-Liang Ko, Chu-Chyn Ou

Förderung

  • Chung Shan Medical University Hospital
  • National Science and Technology Council

Zitieren

APA

Leong, P. Y., Chuang, W. C., Ko, J. L., Liao, J. W., Chen, L. C., Tsai, Y. H., & Ou, C. C. (2026). A Probiotic Combination of Limosilactobacillus reuteri and Clostridium butyricum Ameliorates 5‐Fluorouracil‐Induced Intestinal Mucositis in Rats by Strengthening Barrier Integrity and Modulating Immuno‐Microbial Homeostasis. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.70183

Vancouver

Leong PY, Chuang WC, Ko JL, Liao JW, Chen LC, Tsai YH, et al. A Probiotic Combination of Limosilactobacillus reuteri and Clostridium butyricum Ameliorates 5‐Fluorouracil‐Induced Intestinal Mucositis in Rats by Strengthening Barrier Integrity and Modulating Immuno‐Microbial Homeostasis. Journal of Cellular Physiology. 2026. doi:10.1002/jcp.70183

BibTeX
@article{Leong2026,
  author = {Leong, Pui-Ying and Chuang, Wen-Chen and Ko, Jiunn-Liang and Liao, Jiunn-Wang and Chen, Liang-Chuan and Tsai, Yi-Hsuan and Ou, Chu-Chyn},
  title = {A Probiotic Combination of Limosilactobacillus reuteri and Clostridium butyricum Ameliorates 5‐Fluorouracil‐Induced Intestinal Mucositis in Rats by Strengthening Barrier Integrity and Modulating Immuno‐Microbial Homeostasis},
  journal = {Journal of Cellular Physiology},
  year = {2026},
  doi = {10.1002/jcp.70183}
}
Kostenlos starten →